


# Accepted Manuscript

Long-term use of inhaled corticosteroids in COPD and the risk of fracture

Anne V. Gonzalez, MD MSc, Janie Coulombe, MSc, Pierre Ernst, MD MSc, Samy Suissa, PhD



PII: S0012-3692(17)31243-6

DOI: [10.1016/j.chest.2017.07.002](https://doi.org/10.1016/j.chest.2017.07.002)

Reference: CHEST 1193

To appear in: *CHEST*

Received Date: 10 April 2017

Revised Date: 26 June 2017

Accepted Date: 5 July 2017

Please cite this article as: Gonzalez AV, Coulombe J, Ernst P, Suissa S, Long-term use of inhaled corticosteroids in COPD and the risk of fracture, *CHEST* (2017), doi: 10.1016/j.chest.2017.07.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Long-term use of inhaled corticosteroids in COPD and the risk of fracture**

Anne V Gonzalez MD MSc<sup>1</sup>, Janie Coulombe MSc<sup>2</sup>, Pierre Ernst MD MSc<sup>2</sup>, Samy Suissa PhD<sup>2</sup>

<sup>1</sup>Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Centre, Montreal, Quebec, Canada

<sup>2</sup>Centre for Clinical Epidemiology, Jewish General Hospital – Lady Davis Research Institute, Montreal, Quebec, Canada

**Correspondence to:**

Pr. Samy Suissa  
Director, Centre for Clinical Epidemiology  
Jewish General Hospital - Lady Davis Research Institute  
3755 Cote Ste-Catherine, H-461, Montreal, Quebec H3T 1E2 Canada  
E-mail: [samy.suissa@mcgill.ca](mailto:samy.suissa@mcgill.ca)

**Short title:** Inhaled corticosteroids and fractures in COPD

**Text words:** 2,771 **Abstract words:** 250 **Tables:** 3 **Figures:** 3 **References:** 29

**Funding:** This research was funded in part by grants from the Canadian Institutes of Health Research (CIHR), Canadian Foundation for Innovation (CFI) and by financial support from Novartis Pharmaceuticals Canada Inc. Dr Gonzalez is the recipient of an FRQS chercheur-boursier clinicien award. Dr. Suissa is the recipient of the James McGill Professorship award.

**Acknowledgements:** The authors thank the Commission d'accès à l'information du Québec for allowing access to the data and the Régie de l'assurance maladie du Québec (RAMQ) for providing the database.

**Prior abstract publication: ERS Congress 2016:** European Respiratory Journal Sep 2016, 48 (suppl 60) PA4048; DOI: 10.1183/13993003.congress-2016.PA4048

**Conflicts of Interest:** Dr. Suissa has received research grants from Boehringer Ingelheim and Novartis. He has also participated in advisory board meetings or as a speaker for AstraZeneca, Boehringer-Ingelheim, Novartis and Pfizer. All others declare no conflicts.

Download English Version:

<https://daneshyari.com/en/article/8658027>

Download Persian Version:

<https://daneshyari.com/article/8658027>

[Daneshyari.com](https://daneshyari.com)